Loading...
•
Dec 31, 2025
Enanta Pharmaceuticals Q1 2026 Earnings Report
Enanta Pharmaceuticals reported financial results for its fiscal first quarter ended December 31, 2025, showing an increase in total revenue and a reduced net loss compared to the previous year.
Key Takeaways
Enanta Pharmaceuticals reported a total revenue of $18.6 million for the fiscal first quarter ended December 31, 2025, an increase from $17.0 million in the same period last year. The company also significantly reduced its net loss to $11.9 million, or $0.42 per diluted common share, compared to a net loss of $22.3 million, or $1.05 per diluted common share, in the prior year.
Total revenue increased to $18.6 million, up from $17.0 million in the prior year, driven by higher AbbVie product sales.
Net loss significantly decreased to $11.9 million ($0.42 per diluted common share) from $22.3 million ($1.05 per diluted common share) in the previous year.
Research and development expenses decreased to $20.9 million, primarily due to lower clinical trial expenses for RSV programs, partially offset by increased immunology program costs.
General and administrative expenses decreased to $9.0 million, mainly due to lower stock-based compensation and legal expenses related to patent infringement lawsuits.
Revenue by Segment
Forward Guidance
Enanta Pharmaceuticals anticipates continued progress in its clinical programs for RSV and preclinical immunology programs, with a strong financial position expected to fund operations into fiscal 2029.
Positive Outlook
- On track to file an IND for EDP-978 in 1Q 2026 and report Phase 1 data in 4Q 2026.
- On track to file an IND for EPS-3903 in 2H 2026.
- Strong financial position of $241.9 million in cash, cash equivalents, and marketable securities, with a cash runway expected to fund operations into fiscal 2029.
- Advancing leading RSV treatment portfolio with preparation for a Phase 3 study for zelicapavir.
- Expanding immunology pipeline with a third program targeting MRGPRX2, with a development candidate expected in 2H 2026.
Challenges Ahead
- Potential impact of development, regulatory, and marketing efforts of others on RSV vaccines and competitive treatments.
- Risks associated with the discovery and development of programs in virology and immunology.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...